Top Industry Leaders in the Plasma Fractionation Market
Latest Plasma Fractionation Companies Update
CSL Behring (Australia)Received FDA approval for the 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for patients with PI and CIPD.Partnered with research institutions to develop novel plasma-derived therapies for unmet medical needs.
Grifols (Spain)Launched their XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG) approved for various primary immunodeficiency diseases in Europe.Focused on expanding their footprint in the growing SCIG market with convenient and patient-preferred delivery options.
Takeda Pharmaceutical (Japan) Collaborated with BPL (UK) to establish a joint venture plasma fractionation facility in India, expanding their global plasma collection and manufacturing capabilities.Focused on developing next-generation plasma-derived medicines with enhanced efficacy and targeted therapeutic applications.
Baxter International Received CE Mark approval for their VIGEVWO™ (immunoglobulin, human-normal, liquid), offering broad-spectrum antibody protection for immune-compromised individuals.Partnered with healthcare providers to improve access to plasma-derived therapies for patients in underserved regions.
Octapharma Signed a strategic partnership with Kedrion (Italy) for collaborative research and development of new plasma-derived medicines, further advancing the field.Emphasized their commitment to sustainable plasma collection practices and environmental responsibility.
List of Plasma Fractionation companies in the market
- CSL Behring (US)
- Grifols Therapeutics (Spain)
- Baxter International Inc (US)
- Mitsubishi Tanabe (Japan)
- Takeda Pharmaceutical (Japan)
- Octapharma AG (Switzerland)
- Hualan Bio (China)
- Kedrion S.p.A (Italy)
- LFB group (France)
- Biotest AG (Germany)